

Camtek

Key Al packaging beneficiary, reiterate Buy

Reiterate Rating: BUY | PO: 90.00 USD | Price: 80.31 USD

Continued order trends and visibility; raise PO to \$90

Reiterate Buy and raise PO to \$90 (on 30x CY25E P/E) from \$75 (26x) on modestly better results/guide and continued order visibility through CY24E. CAMT remains a key beneficiary of the rising demand for Al-related heterogeneous integration (HI) chiplets and HBM tools, and we expect continued WFE outgrowth in CY24E at +24% YoY (+14% organically) vs. just +5% for the broader industry. Despite modestly higher OSAT mix in orders QTD (MarQ), CAMT reiterated its HBM/HI tool mix goal of >30% this year, with additional "substantial orders" anticipated to land in 2H. Particularly, there are no signs of slowing demand amid continued customer deployment of advanced packaging for HBM (memory for AI GPUs) and chiplets (AI CPUs, GPUs), and the ramp of AI at the edge (PCs, smartphones, etc.) should further increase opportunities for CAMT in the coming years. While the addition of FormFactor's FRT business is modestly OpM dilutive in the near-term, we eventually expect a 30%+ OpM run-rate on continued sales growth, margin improvements (opex synergies, new platform launches) by CY25E, above mgmt's long-term target of ~26.5%. Overall, we tweak CY24/25E sales by +1%/+2% and pf-EPS by +6%/+5%. Our new 30x CY25E P/E is above peers (20x-26x) but within CAMT's I-t (8x-40x) range and is justified by CAMT's high growth and exposure to key Al segments.

Likes: Al packaging tools, CY24 visibility, OSAT strengths

(1) CAMT is a key beneficiary of rising demand for HI (chiplets) and HBM tools, with strong backlog at all leading DRAM and chiplet (TSMC/Intel) vendors. (2) CAMT has received 300 system tool orders since in 2H'23 (up from 240 announced in November), most of which should ship throughout CY24E and giving great visibility amid signs of potential trailing-edge weaknesses (per GFS, AMAT). (3) OSAT (non-HBM, non-chiplet) advanced packaging customers will comprise of ~35% of sales in CY24E, with strong early-year order trends particularly driven by Chinese customers.

Risks: Premium multiple, HBM/chiplet mix, restrictions

(1) CAMT has continued to outperform the SOX (\pm 20% YTD vs. SOX \pm 6%), and multiple has increased to 32x NTM P/E (ex-cash) today vs. just 11x twelve months ago, though still within Camtek's I-t 8-40x range. (2) While mgmt reiterated HBM/chiplet tool mix of 30%+ in CY24E, we highlight a potential mix shift toward more OSAT-based customers could dent the current high valuation built on Al excitement. (3) High China exposure (\pm 45% of sales) could be impacted by a potential broadening of trade restrictions.

Estimates (Dec) (US\$)	2022A	2023A	2024E	2025E	2026E
EPS	1.88	1.96	2.40	2.79	3.15
GAAP EPS	1.66	1.61	1.93	2.30	2.63
EPS Change (YoY)	19.0%	4.3%	22.4%	16.3%	12.9%
Consensus EPS (Bloomberg)			2.32	2.79	NA
DPS	0	0	0	0	0
Valuation (Dec)					
P/E	46.7x	44.8x	36.6x	31.5x	27.9x
GAAP P/E	52.9x	54.5x	45.5x	38.2x	33.4x
EV / EBITDA*	40.5x	44.6x	33.8x	27.8x	23.8x
Free Cash Flow Yield*	1.3%	1.8%	2.8%	3.4%	4.0%
* For full definitions of <i>IQ</i> method SM measures, see page 10.					

BofA Securities does and seeks to do business with issuers covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Refer to important disclosures on page 11 to 13. Analyst Certification on page 9. Price Objective Basis/Risk on page 9.

20 February 2024

Equity

Key Changes		
(US\$)	Previous	Current
Price Obj.	75.00	90.00
2024E Rev (m)	385.2	390.4
2025E Rev (m)	432.4	443.0
2026E Rev (m)	NA	492.0
2024E EPS	2.26	2.40
2025E EPS	2.66	2.79
2026E EPS	NA	3.15

Vivek Arya

Research Analyst BofAS vivek.arya@bofa.com

Blake Friedman

Research Analyst BofAS blake.friedman@bofa.com

Duksan Jang

Research Analyst BofAS

duksan.jang@bofa.com

Lauren Guy Research Analyst

lauren.guy2@bofa.com

Stock Data

Price	80.31 USD
Price Objective	90.00 USD
Date Established	20-Feb-2024
Investment Opinion	C-1-9
52-Week Range	24.81 USD - 89.65 USD
Mrkt Val (mn) / Shares Out	3,604 USD / 44.9
(mn)	
Free Float	60.9%
Average Daily Value (mn)	33.35 USD
BofA Ticker / Exchange	CAMT / NAS
Bloomberg / Reuters	CAMT US / CAMT.OQ
ROE (2024E)	22.3%
Net Dbt to Eqty (Dec-2023A)	-25.2%
ESGMeter™	Low

ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of BofA Global Research's equity investment rating, volatility risk rating, income rating, and price objective for that company. For full details, refer to "BofA ESGMeter Methodology".

See page 5 for abbreviations

iQprofile[™] Camtek

IQmethod - Bus Performance*					
(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Return on Capital Employed	16.4%	14.8%	15.8%	16.0%	15.7%
Return on Equity	26.7%	22.3%	22.3%	21.4%	20.0%
Operating Margin	28.7%	26.4%	28.3%	30.4%	32.0%
Free Cash Flow	50	71	109	133	159

*i***Q**method SM − **Quality of Earnings***

(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Cash Realization Ratio	0.6x	0.8x	1.0x	1.0x	1.1x
Asset Replacement Ratio	1.6x	1.7x	1.7x	1.7x	1.7x
Tax Rate	9.3%	10.3%	8.7%	8.9%	9.1%
Net Debt-to-Equity Ratio	-38.6%	-25.2%	-38.7%	-49.7%	-58.7%
Interest Cover	NA	NA	NA	NA	NA

Income Statement Data (Dec)

(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Sales	321	315	390	443	492
% Change	19.0%	-1.7%	23.8%	13.5%	11.0%
Gross Profit	161	153	196	227	256
% Change	16.7%	-5.2%	28.6%	15.6%	12.6%
EBITDA	97	88	116	141	165
% Change	21.8%	-9.0%	32.0%	21.4%	16.6%
Net Interest & Other Income	7	22	21	21	21
Net Income (Adjusted)	90	96	119	141	161
% Change	26.7%	5.8%	24.4%	18.3%	14.6%

Free Cash Flow Data (Dec)

(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Net Income from Cont Operations (GAAP)	80	79	96	116	135
Depreciation & Amortization	5	5	6	7	7
Change in Working Capital	(31)	(17)	4	7	13
Deferred Taxation Charge	0	0	0	0	0
Other Adjustments, Net	4	12	13	14	16
Capital Expenditure	(8)	(8)	(10)	(11)	(12)
Free Cash Flow	50	71	109	133	159
% Change	-12.4%	43.6%	52.1%	22.0%	19.7%
Share / Issue Repurchase	0	0	0	0	0
Cost of Dividends Paid	0	0	0	0	0
Change in Debt	0	0	0	0	0

Balance Sheet Data (Dec)

(US\$ Millions)	2022A	2023A	2024E	2025E	2026E
Cash & Equivalents	148	120	229	361	520
Trade Receivables	81	87	91	93	92
Other Current Assets	328	340	338	336	331
Property, Plant & Equipment	33	42	52	63	75
Other Non-Current Assets	87	199	199	199	199
Total Assets	677	788	908	1,052	1,217
Short-Term Debt	0	0	0	0	0
Other Current Liabilities	89	97	102	110	117
Long-Term Debt	0	0	0	0	0
Other Non-Current Liabilities	204	215	215	215	215
Total Liabilities	293	312	317	325	332
Total Equity	384	476	590	727	886
Total Equity & Liabilities	677	788	908	1,052	1,217

^{*} For full definitions of $\emph{IQ} \textit{method}^{\text{SM}}$ measures, see page 10.

Company Sector

Semiconductor Capital Equipment

Company Description

Camtek is an Israeli-based SMid-cap semicap equipment vendor focused on developing high-end inspection and metrology equipment for the semiconductor industry.

Camtek's system inspect and measure wafers throughout the production process to improve yield and ensure only good wafers are shipped to end users. Their tools address front-end macro inspection and outgoing Quality Control (OQC), inspection and metrology of bumps in the mid-end, and inspection of post-diced wafers in the back-end.

Investment Rationale

We rate Camtek Buy. We like Camtek's strong product portfolio, share gains, and exposure to key growth markets across advanced packaging for high performance logic and memory, compound semis for electric vehicles, and CMOS image sensors for 5G smartphones.

Stock Data

Average Daily Volume 415,247

Quarterly Earnings Estimates

	2023	2024
Q1	0.42A	0.57E
Q2	0.45A	0.58E
Q3	0.51A	0.62E
Q4	0.57A	0.62E



Summary of model changes

Exhibit 1: Summary of estimate changes

We adjust our CY24/25E sales by +\$5mn/+\$11mn and EPS by +\$0.13/+\$0.13

	Si	ales (\$mn)		No	on-GAAP EPS	5
	Old	NEW	delta	Old	NEW	delta
Mar-23	\$72	\$72	\$0	\$0.42	\$0.42	\$0.00
Jun-23	\$74	\$74	\$0	\$0.45	\$0.45	\$0.00
Sep-23	\$80	\$80	\$0	\$0.51	\$0.51	\$0.00
Dec-23	\$88	\$89	\$1	\$0.51	\$0.57	\$0.06
FY23E	\$315	\$315	\$1	\$1.90	\$1.96	\$0.06
YoY%	-1.9%	-1.7%	0.2%	1.2%	4.6%	3.4%
Mar-24E	\$92	\$94	\$2	\$0.52	\$0.57	\$0.04
Jun-24E	\$95	\$96	\$1	\$0.56	\$0.58	\$0.03
Sep-24E	\$98	\$99	\$1	\$0.59	\$0.62	\$0.03
Dec-24E	\$100	\$101	\$1	\$0.59	\$0.62	\$0.03
FY24E	\$385	\$390	\$5	\$2.26	\$2.40	\$0.13
YoY%	22.4%	23.8%	1.3%	19.3%	22.2%	5.9%
Mar-25E	\$104	\$106	\$2	\$0.64	\$0.67	\$0.04
Jun-25E	\$107	\$109	\$3	\$0.65	\$0.69	\$0.04
Sep-25E	\$109	\$112	\$3	\$0.68	\$0.71	\$0.03
Dec-25E	\$112	\$115	\$3	\$0.69	\$0.71	\$0.02
FY25E	\$432	\$443	\$11	\$2.66	\$2.79	\$0.13
YoY%	12.2%	13.5%	2.5%	17.6%	16.5%	4.9%

Source: BofA Global Research estimates, company reports

BofA GLOBAL RESEARCH

DecQ reported vs. expectations

Exhibit 2: Summary of DecQ earnings results vs. our/Consensus expectations

DecQ sales were 1% above initial guidance. EPS came in 4c ahead of the Street

	Dec-22	Sep-23	Dec-23						
			Original Guidance	Consensus	BofA	Reported	Delta	QoQ	YoY
Sales (\$mn)	\$82.2	\$80.5	\$88.0	\$88.0	\$88.1	\$88.7	0.7%	10.2%	7.9%
QoQ%	0.2%	9.1%			9.5%	10.2%			
YoY%	10.8%	-1.9%			7.2%	7.9%			
Gross Margin % (GAAP)	48.6%	48.5%			48.6%	44.9%	-376	-361	-375
Gross Margin % (Non-GAAP)	49.0%	49.0%		49.2%	49.1%	49.2%	19	29	28
Gross Profit (GAAP)	39.9	39.0			42.8	39.8	-7.1%	2.0%	-0.4%
Gross Profit (Non-GAAP)	40.2	39.4			43.2	43.7	1.0%	10.9%	8.5%
R&D	6.7	7.8			9.3	8.0	-13.6%	3.7%	20.3%
SG&A	12.8	12.2			13.4	14.5	8.4%	19.2%	13.5%
Opex Total (GAAP)	19.5	19.9			22.7	22.6	-0.6%	13.2%	15.8%
Opex Total (Non-GAAP)	17.4	17.2			19.7	18.2	-7.6%	5.7%	4.4%
Operating Income (GAAP)	20.5	19.1			20.1	17.2	-14.4%	-9.7%	-15.8%
Operating Income (Non-GAAP)	22.8	22.2		24.4	23.6	25.5	8.2%	14.8%	11.7%
Operating Margin % (GAAP)	24.9%	23.7%			22.8%	19.4%	-343	-428	-548
Operating Margin % (Non-GAAP)	27.8%	27.6%		27.7%	26.7%	28.7%	200	115	96
Pretax Income (GAAP)	24.3	24.7			24.4	22.9	6.4%	10.8%	14.6%
Pretax Income (Non-GAAP)	26.6	27.9			27.9	31.2	-4.0%	-5.7%	-4.1%
Tax Rate (Non-GAAP)	9.7%	9.6%			10.0%	9.5%	12.4%	12.0%	17.3%
Tax expense (Non-GAAP)	-2.6	-2.7			-2.8	-3.0	-4.0%	-6.1%	-5.7%
Net Income (GAAP)	21.7	22.1			21.7	20.8	12.4%	11.5%	15.3%
Net Income (Non-GAAP)	24.0	25.2			25.1	28.2	0.0%	0.4%	1.7%
Diluted EPS (GAAP)	\$0.45	\$0.45			\$0.44	\$0.42	-4.0%	-6.1%	-5.7%
Diluted EPS (Non-GAAP)	\$0.50	\$0.51		\$0.53	\$0.51	\$0.57	12.4%	11.5%	15.3%
Diluted Shares	48.3	49.0			49.2	49.1	0.0%	0.4%	1.7%

Source: BofA Global Research estimates, company reports, Bloomberg



MarQ guidance vs. expectations

Exhibit 3: DecQ guidance vs. our/Consensus expectations

MarQ sales guided \$2.0mn above consensus

	Dec-23		Mar-	24E	
	Actual	Old BofA	Consensus	Guidance	New BofA
Sales (\$mn)	\$88.7	\$91.6	\$92.0	\$94.0	\$94.0
QoQ%		4.0%			6.0%
YoY%		26.5%			29.7%
Gross Margin % (GAAP)	44.9%	48.9%			45.4%
Gross Margin % (Non-GAAP)	49.2%	49.4%	49.4%		49.5%
Gross Profit (GAAP)	39.8	44.8			42.7
Gross Profit (Non-GAAP)	43.7	45.2			46.6
R&D	8.0	10.0			8.5
SG&A	14.5	13.9			15.1
Opex Total (GAAP)	22.6	23.9			23.6
Opex Total (Non-GAAP)	18.2	20.8			21.0
Operating Income (GAAP)	17.2	20.9			19.1
Operating Income (Non-GAAP)	25.5	24.5	25		25.6
Operating Margin % (GAAP)	19.4%	22.8%			20.3%
Operating Margin % (Non-GAAP)	28.7%	26.7%	27.3%		27.3%
Pretax Income (GAAP)	22.9	25.2			24.4
Pretax Income (Non-GAAP)	31.2	28.8			30.9
Tax Rate (Non-GAAP)	9.5%	10.0%			9.5%
Tax expense (Non-GAAP)	-3.0	-2.9			-2.9
Net Income (GAAP)	20.8	22.3			22.3
Net Income (Non-GAAP)	28.2	25.9			28.0
Diluted EPS (GAAP)	\$0.42	\$0.45			\$0.45
Diluted EPS (Non-GAAP)	\$0.57	\$0.52	\$0.54		\$0.57
Diluted Shares	49.1	49.4			49.3

Source: BofA Global Research estimates, company reports, Bloomberg

BofA GLOBAL RESEARCH

Balance sheet & cash flow snapshot

Exhibit 4: Summary of balance sheet and cash flow statement

Net cash decreased QoQ; inventory \$s increased and days increased QoQ

	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23	QoQ	YoY
Total cash	\$479	\$493	\$506	\$517	\$449	-13.2%	-6.3%
ST debt	\$0	-	-	-	\$0		
LT debt	\$196	196	196	197	\$197		
Total debt	\$196	196	196	197	197		
Net cash	\$283	297	310	321	252	-21.4%	-11.0%
Net cash / share	\$5.86	\$6.13	\$6.37	\$6.55	\$5.12	-21.7%	-12.5%
Days sales outstanding (DSO)	89.3	83.3	97.5	103.3	89.6		
Days payables outstanding (DPO)	68.2	66.2	73.3	74.0	78.5		
Inventory \$	\$66	\$65	\$61	\$65	\$86	32.7%	31.1%
Inventory turns	2.6	2.4	2.5	2.6	2.3		
Inventory days	141.6	152.6	144.0	142.4	160.3	17.9	18.7
Cash conversion days	162.7	169.7	168.2	171.8	171.4		
Cash flow from ops	\$20	\$17	\$16	\$12	\$34	175.8%	74.5%

Source: BofA Global Research estimates, company reports, Bloomberg



Glossary

CAMT: Camtek;

WFE: Wafer Fab Equipment;

IDM: Integrated Device Manufacturer;

DRAM: Dynamic Random Access Memory;

HBM: High Bandwidth Memory;

DDR: Double-Data Rate;

SiC: Silicon Carbide;

HI: Heterogeneous Integration;

ASP: Average Selling Price;

FRT: FRT GmbH;

GFS: GlobalFoundries;

AMAT: Applied Materials

MU: Micron

TSMC: Taiwan Semiconductor

GPU: graphic processing unit

CPU: central processing unit



Exhibit 5: CAMT Income Statement (\$mn)CAMT reported \$89mn in sales and 57c in EPS in DecQ

	Q1	Q2	Q3	Q4	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E	FY23E	FY24E	FY25E	FY26E
FY (December)	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24E	Jun-24E	Sep-24E	Dec-24E	Mar-25E	Jun-25E	Sep-25E	Dec-25E	Dec-23	Dec-24	Dec-25	Dec-26
Revenues	\$72	\$74	\$80	\$89	\$94	\$96	\$99	\$101	\$106	\$109	\$112	\$115	\$315	\$390	\$443	\$492
QoQ	-12%	2%	9%	10%	6%	2%	4%	2%	5%	3%	3%	3%				
YoY	-6%	-7%	-2%	8%	30%	30%	23%	14%	13%	14%	13%	14%	-2%	24%	13%	11%
Cost of Sales	39	39	41	49	51	52	53	54	56	57	58	60	168	210	232	252
Gross Profit (GAAP)	34	35	39	40	43	44	46	48	50	52	54	56	148	181	212	240
Gross Profit (Non-GAAP)	34	35	39	44	47	48	50	52	54	56	58	59	153	196	227	256
R&D Expense	8	8	8	8	8	9	8	9	9	10	10	10	31	34	39	43
SG&A Expense	12	12	12	15	15	15	16	16	16	16	17	18	51	63	67	70
Total Opex (GAAP)	20	20	20	23	24	24	24	25	25	26	27	28	82	97	105	113
Total Opex (Non-GAAP)	17	17	17	18	21	21	21	22	22	23	23	25	69	86	93	98
Operating Income (GAAP)	14	15	19	17	19	20	22	22	25	26	27	27	65	84	106	127
Operating Income (Non-GAAP)	17	18	22	25	26	27	29	29	32	33	34	35	83	110	135	157
Figure 1 (CAAD)	_	C	_	<u></u>	_	_	5	_	_	_	_	_	22	21	21	21
Financing/Other Income (GAAP) Financing/Other Income (Non-GAAP)	5 5	6 6	6	6 6	5 5	5 5	5 5	5 5	5 5	5	5 5	5 5	22 22	21 21	21 21	21 21
Pretax Income (GAAP)	19	21	25	23	24	25	28	28	30	32	33	33	88	105	127	148
Pretax Income (MAAF)	22	21	28	31	31	32	34	34	37	39	40	40	106	132	156	178
Pretax income (Non-GAAP)	22	24	20	31	31	32	34	34	37	39	40	40	100	132	130	1/0
Net Income (GAAP)	17	19	22	21	22	23	25	25	28	29	30	30	79	96	116	135
Net Income (Non-GAAP)	20	22	25	28	28	29	31	31	34	35	36	36	96	119	141	161
Diluted EPS (GAAP)	\$0.36	\$0.38	\$0.45	\$0.42	\$0.45	\$0.47	\$0.51	\$0.51	\$0.55	\$0.57	\$0.59	\$0.59	\$1.61	\$1.93	\$2.30	\$2.63
Diluted EPS (Non-GAAP)	\$0.42	\$0.45	\$0.51	\$0.57	\$0.57	\$0.58	\$0.62	\$0.62	\$0.67	\$0.69	\$0.71	\$0.71	\$1.96	\$2.40	\$2.79	\$3.15
YoY	-3%	-2%	7%	15%	34%	30%	21%	9%	19%	19%	14%	14%	5%	22%	16%	13%
Diluted Shares (Non-GAAP)	48	49	49	49	49	50	50	50	50	50	51	51	49	50	50	51
Margin Analysis (Non-GAAP)																
Gross Margin	47.3%	48.0%	49.0%	49.2%	49.5%	50.0%	50.6%	50.9%	50.8%	51.0%	51.4%	51.6%	48.4%	50.3%	51.3%	52.0%
R&D (GAAP)	10.4%	11.0%	9.6%	9.1%	9.0%	9.1%	8.4%	8.7%	8.6%	8.7%	8.7%	8.9%	10.0%	8.8%	8.7%	8.7%
SG&A (GAAP)	16.7%	16.2%	15.1%	16.4%	16.1%	16.0%	15.9%	16.2%	14.9%	14.8%	15.0%	15.5%	16.1%	16.1%	15.0%	14.2%
Opex	23.3%	23.2%	21.4%	20.5%	22.3%	22.3%	21.5%	22.1%	20.7%	20.6%	20.8%	21.5%	22.0%	22.0%	20.9%	20.0%
Operating Margin	24.0%	24.8%	27.6%	28.7%	27.3%	27.8%	29.2%	28.9%	30.2%	30.4%	30.7%	30.2%	26.4%	28.3%	30.4%	32.0%
Tax rate	9.2%	8.9%	9.6%	9.5%	9.5%	9.5%	9.5%	9.5%	9.5%	9.5%	9.5%	9.5%	9.3%	9.5%	9.5%	9.5%
Net Income	28.2%	29.6%	31.3%	31.8%	29.7%	30.1%	31.2%	30.8%	31.8%	31.9%	32.0%	31.5%	30.3%	30.5%	31.8%	32.8%
	20.2 /0	23.0 /0	31.570	31.070	23.7 /0	50.170	J 1.2 /0	30.070	31.070	51.570	52.0 /0	51.570	50.5 /0	30.370	31.070	32.0 /0

Source: BofA Global Research estimates, company reports



Exhibit 6: CAMT – Balance Sheet (\$mn)
CAMT has a strong balance sheet with \$5.12 in cash per share



	Q1	Q2	Q3	Q4	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E	FY23E		FY25E	
FY (December)	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24E	Jun-24E	Sep-24E	Dec-24E	Mar-25E	Jun-25E	Sep-25E	Dec-25E	Dec-23	Dec-24	Dec-25	Dec-26
Assets																
Cash and cash equivalents	189	233	168	120	145	172	203	229	262	293	332	361	120	229	361	520
Short-term deposits	227	199	222	234	234	234	234	234	234	234	234	234	234	234	234	234
Trade accounts receivable, net	66	79	91	87	89	88	89	91	92	91	91	93	87	91	93	92
Inventories	65	61	65	86	87	87	83	84	84	86	81	82	86	84	82	77
Other current assets	15	15	17	20	20	20	20	20	20	20	20	20	20	20	20	20
Total current assets	562	587	562	547	575	601	629	657	691	724	757	790	547	657	790	943
Long-term deposits	77	75	127	95	95	95	95	95	95	95	95	95	95	95	95	95
Long-term inventory	7	7	8	9	9	9	9	9	9	9	9	9	9	9	9	9
Deferred tax assets	1	1	1	3	3	3	3	3	3	3	3	3	3	3	3	3
Other assets, net	2	3	2	1	1	1	1	1	1	1	1	1	1	1	1	1
Property and equipment, net	35	37	37	42	44	47	49	52	54	57	60	63	42	52	63	75
Intangible assets, net	1	1	1	91	91	91	91	91	91	91	91	91	91	91	91	91
Total Assets	683	710	738	788	818	846	877	908	945	980	1,016	1,052	788	908	1,052	1,217
Liabilities & Equity																
Trade accounts payable	28	31	34	42	46	46	47	48	52	53	54	55	42	48	55	62
Other current liabilities	26 46	46	46	54	54	54	54	54	54	54	54	54	54	54	54	54
Total current liabilities	74	77	80	97	100	101	102	102	107	108	109	110	97	102	110	117
Total current habilities	/-	,,	00	31	100	101	102	102	107	100	103	110	31	102	110	117
Deferred tax liabilities, net	0	0	0	8	8	8	8	8	8	8	8	8	8	8	8	8
Other long-term liabilities	204	206	207	207	207	207	207	207	207	207	207	207	207	207	207	207
Total Liabilities	279	283	287	312	315	316	317	317	321	323	324	325	312	317	325	332
Total shareholders' equity	405	426	452	476	503	531	560	590	623	657	692	727	476	590	727	886
Total Liab. & Stock Equity	683	710	738	788	818	846	877	908	945	980	1,016	1,052	788	908	1,052	1,217
											-,	-,			-,	-,
Cash and Liquidity Ratios																
Total Cash	493	506	517	449	474	501	532	557	590	622	660	690	449	557	690	849
Short-term debt	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long-term debt	196	196	197	197	197	197	197	197	197	197	197	197	197	197	197	197
Total debt	196	196	197	197	197	197	197	197	197	197	197	197	197	197	197	197
Net Cash	297	310	321	252	277	304	335	361	393	425	464	493	252	361	493	652
Net Cash/dil. share	\$6.13	\$6.37	\$6.55	\$5.12	\$5.61	\$6.13	\$6.74	\$7.22	\$7.84	\$8.45	\$9.17	\$9.72	\$5.16	\$7.26	\$9.78	\$12.72
Cash conversion ratios																
Days Sales Outstanding (DSO)	83.3	97.5	103.3	89.6	86.6	83.6	81.6	81.6	78.6	75.6	73.6	73.6				
Payable Days (DPO)	66.2	73.3	74.0	78.5	81.5	81.5	81.5	81.5	84.5	84.5	84.5	84.5				
Inventory Days (DIO)	152.6	144.0	142.4	160.3	154.3	153.3	143.3	143.3	137.3	136.3	126.3	126.3				
Cash Conversion Days	169.7	168.2	171.8	171.4	159.4	155.4	143.4	143.4	131.4	127.4	115.4	115.4				
Cush conversion buys	. 55.7			.,	.55.1	.55.1	5.1	5]								

Source: BofA Global Research estimates, company reports

Exhibit 7: CAMT – Cash Flow Statement (\$mn) CAMT should maintain FCF margins above 15%

	Q1	Q2	Q3	Q4	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E	FY23E	FY24E	FY25E	FY26E
FY (December)	Mar-23	Jun-23	Sep-23	Dec-23	Mar-24E	Jun-24E	Sep-24E	Dec-24E	Mar-25E	Jun-25E	Sep-25E	Dec-25E	Dec-23	Dec-24	Dec-25	Dec-26
Operating Activities																
Net income	17	19	22	21	22	23	25	25	28	29	30	30	79	96	116	135
Depreciation and Amortization	1	1	1	1	1	1	1	2	2	2	2	2	5	6	7	7
Stock-based compensation	3	3	3	3	3	3	3	3	3	4	4	4	13	13	14	16
Changes in operating assets and liabilities																
Trade accounts receivable	14	(13)	(12)	4	(2)	1	(1)	(2)	(1)	1	0	(2)	(7)	(3)	(2)	1
Inventories	1	3	(4)	(21)	(1)	(0)	4	(1)	(0)	(1)	5	(2)	(20)	2	2	5
Trade accounts payable	(4)	3	2	8	4	0	1	1	4	1	1	1	11	6	7	7
Cash From Operations	17	16	12	34	28	29	34	28	36	35	41	32	79	118	144	171
Investing Activities																
Investment in short-term deposits	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Purchase of fixed assets	(2)	(2)	(2)	(2)	(2)	(2)	(2)	(3)	(3)	(3)	(3)	(3)	(8)	(10)	(11)	(12)
Cash From Investing	(2)	(2)	(2)	(2)	(2)	(2)	(2)	(3)	(3)	(3)	(3)	(3)	(8)	(10)	(11)	(12)
Financing Activities																
Share issuance, net	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Proceeds from exercise of share options	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Dividend payments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash From Financing	26	30	(76)	(80)	0	0	0	0	0	0	0	0	(100)	0	0	0
Net Change in Cash/Eqv.	41	44	(65)	(48)	25	27	31	25	33	32	38	30	(28)	109	133	159
Cash/Eqv. at beginning of period	148	189	233	168	120	145	172	203	229	262	293	332	148	120	229	361
Cash/Eqv. at end of period	189	233	168	120	145	172	203	229	262	293	332	361	120	229	361	520
Free Cash Flow	15	14	10	32	25	27	31	25	33	32	38	30	71	109	133	159
TTM FCF	69	71	58	71	82	95	116	109	116	122	128	133				
TTM FCF Margin	21.7%	22.8%	18.7%	22.7%	24.2%	26.4%	30.6%	27.9%	28.9%	29.2%	29.9%	29.9%	22.7%	27.9%	29.9%	32.3%

Source: BofA Global Research estimates, company reports



Price objective basis & risk

Camtek (CAMT)

We assign a \$90 PO which is based on 30x our non-GAAP CY25E EPS adjusted for net cash. This is well within Camtek's long-term 8x-40x range and a bit above other semicap peers which we think is fair given similar growth prospects.

Upside risks: (1) accelerated share gains vs. key competitor, Onto Innovations. (2) stronger than expected electronics demand that would tighten up semiconductor capacity further, driving increased semiconductor equipment sales. (3) potential as a target of industry consolidation.

Downside risks: (1) Slower than expected capital spending cycle. (2) heightened competition with larger players like KLA Corp. (3) historically cyclical nature of semiconductor capital spending, particularly on packaging equipment. (4) further restrictions on companies in China/Asia given high relative exposure, 5) Geopolitics conflicts.

Analyst Certification

I, Vivek Arya, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or view expressed in this research report.

US - Semiconductors and Semiconductor Capital Equipment Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
BUY				
	Advanced Micro Devices, Inc	AMD	AMD US	Vivek Arya
	Analog Devices Inc.	ADI	ADI US	Vivek Arya
	Applied Materials, Inc.	AMAT	AMAT US	Vivek Arya
	Arm Holdings	ARM	ARM US	Vivek Arya
	Broadcom Inc	AVGO	AVGO US	Vivek Arya
	Cadence	CDNS	CDNS US	Vivek Arya
	Camtek	CAMT	CAMT US	Vivek Arya
	KLA Corporation	KLAC	KLAC US	Vivek Arya
	Lam Research Corp.	LRCX	LRCX US	Vivek Arya
	M/A-Com	MTSI	MTSI US	Vivek Arya
	Marvell Technology Group Ltd.	MRVL	MRVL US	Vivek Arya
	Microchip	MCHP	MCHP US	Vivek Arya
	Micron Technology, Inc	MU	MU US	Vivek Arya
	Nova	NVMI	NVMI US	Vivek Arya
	NVIDIA Corporation	NVDA	NVDA US	Vivek Arya
	NXP Semiconductors NV	NXPI	NXPI US	Vivek Arya
	onsemi	ON	ON US	Vivek Arya
	Synopsys	SNPS	SNPS US	Vivek Arya
NEUTRAL				
	Advanced Energy Industries	AEIS	AEIS US	Duksan Jang
	Allegro MicroSystems	ALGM	ALGM US	Blake Friedman
	Axcelis Technologies	ACLS	ACLS US	Duksan Jang
	Coherent Corp	COHR	COHR US	Vivek Arya
	GlobalFoundries	GFS	GFS US	Vivek Arya
	Intel	INTC	INTC US	Vivek Arya
	Lattice Semiconductor	LSCC	LSCC US	Blake Friedman
	Texas Instruments Inc.	TXN	TXN US	Vivek Arya
UNDERPERFORM				
	Ambarella	AMBA	AMBA US	Vivek Arya
	Credo Technology	CRDO	CRDO US	Vivek Arya
	Lumentum Holdings	LITE	LITE US	Vivek Arya



US - Semiconductors and Semiconductor Capital Equipment Coverage Cluster

Investment rating	Company	BofA Ticker	Bloomberg symbol	Analyst
	Qorvo Inc.	QRVO	QRVO US	Vivek Arya
	Skyworks Solutions, Inc.	SWKS	SWKS US	Vivek Arya
	Teradyne	TER	TER US	Vivek Arya
	Wolfspeed Inc	WOLF	WOLF US	Vivek Arya

IQmethod[™] Measures Definitions

Business Performance	Numerator	Denominator
Return On Capital Employed	NOPAT = (EBIT + Interest Income) \times (1 – Tax Rate) + Goodwill Amortization	Total Assets — Current Liabilities + ST Debt + Accumulated Goodwill Amortization
Return On Equity	Net Income	Shareholders' Equity
Operating Margin	Operating Profit	Sales
Earnings Growth	Expected 5 Year CAGR From Latest Actual	N/A
Free Cash Flow	Cash Flow From Operations — Total Capex	N/A
Quality of Earnings	Numerator	Denominator
Cash Realization Ratio	Cash Flow From Operations	Net Income
Asset Replacement Ratio	Capex	Depreciation
Tax Rate	Tax Charge	Pre-Tax Income
Net Debt-To-Equity Ratio	Net Debt = Total Debt - Cash & Equivalents	Total Equity
Interest Cover	EBIT	Interest Expense
Valuation Toolkit	Numerator	Denominator
Price / Earnings Ratio	Current Share Price	Diluted Earnings Per Share (Basis As Specified)
Price / Book Value	Current Share Price	Shareholders' Equity / Current Basic Shares
Dividend Yield	Annualised Declared Cash Dividend	Current Share Price
Free Cash Flow Yield	Cash Flow From Operations – Total Capex	Market Cap = Current Share Price × Current Basic Shares
Enterprise Value / Sales	EV = Current Share Price × Current Shares + Minority Equity + Net Debt +	Sales
	Other LT Liabilities	
EV / EBITDA	Enterprise Value	Basic EBIT + Depreciation + Amortization

Monethod Suis the set of BofA Global Research standard measures that serve to maintain global consistency under three broad headings: Business Performance, Quality of Earnings, and validations. The key features of iQmethod are: A consistently structured, detailed, and transparent methodology. Guidelines to maximize the effectiveness of the comparative valuation process, and to identify some common pitfalls.

Redatabase is our real-time global research database that is sourced directly from our equity analysts' earnings models and includes forecasted as well as historical data for income statements, balance sheets, and cash flow statements for companies covered by BofA Global Research.


*IQ*profileSM, *IQ*methodSM are service marks of Bank of America Corporation. *IQ*database[®] is a registered service mark of Bank of America Corporation.



Disclosures

Important Disclosures

Camtek (CAMT) Price Chart



B: Buy, N: Neutral, U: Underperform, PO: Price Objective, NA: No longer valid, NR: No Rating

The Investment Opinion System is contained at the end of the report under the heading "Fundamental Equity Opinion Key". Dark grey shading indicates the security is restricted with the opinion suspended. Medium grey shading indicates the security is under review with the opinion withdrawn. Light grey shading indicates the security is not covered. Chart is current as of a date no more than one trading day prior to the date of the report.

Equity Investment Rating Distribution: Technology Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	215	53.09%	Buy	111	51.63%
Hold	97	23.95%	Hold	45	46.39%
Sell	93	22.96%	Sell	24	25.81%

Equity Investment Rating Distribution: Global Group (as of 31 Dec 2023)

Coverage Universe	Count	Percent	Inv. Banking Relationships R1	Count	Percent
Buy	1895	53.62%	Buy	1083	57.15%
Hold	832	23.54%	Hold	454	54.57%
Sell	807	22.84%	Sell	383	47.46%

R1 Issuers that were investment banking clients of BofA Securities or one of its affiliates within the past 12 months. For purposes of this Investment Rating Distribution, the coverage universe includes only stocks. A stock rated Neutral is included as a Hold, and a stock rated Underperform is included as a Sell.

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperform stocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating Total return expectation (within 12-month period of date of initial rating) Ratings dispersion guidelines for coverage cluster^{R2}

Buy	≥ 10%	≤ 70%
Neutral	≥ 0%	≤ 30%
nderperform	N/A	≥ 20%

R2Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

Price Charts for the securities referenced in this research report are available on the <u>Price Charts website</u>, or call 1-800-MERRILL to have them mailed. BofAS or one of its affiliates acts as a market maker for the equity securities recommended in the report: Camtek.

BofAS or an affiliate has received compensation from the issuer for non-investment banking services or products within the past 12 months: Camtek.

The issuer is or was, within the last 12 months, a non-securities business client of BofAS and/or one or more of its affiliates: Camtek.

BofAS or one of its affiliates is willing to sell to, or buy from, clients the common equity of the issuer on a principal basis: Camtek.

BofA Global Research personnel (including the analyst(s) responsible for this report) receive compensation based upon, among other factors, the overall profitability of Bank of America Corporation, including profits derived from investment banking. The analyst(s) responsible for this report may also receive compensation based upon, among other factors, the overall profitability of the Bank's sales and trading businesses relating to the class of securities or financial instruments for which such analyst is responsible.



Other Important Disclosures

From time to time research analysts conduct site visits of covered issuers. BofA Global Research policies prohibit research analysts from accepting payment or reimbursement for travel expenses from the issuer for such visits.

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

Recipients who are not institutional investors or market professionals should seek the advice of their independent financial advisor before considering information in this report in connection with any investment decision, or for a necessary explanation of its contents.

Officers of BofAS or one or more of its affiliates (other than research analysts) may have a financial interest in securities of the issuer(s) or in related investments. Refer to BofA Global Research policies relating to conflicts of interest.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Research Reports:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator); Merrill Lynch (South Africa); Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK); Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorite regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI); BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Canada): Merrill Lynch (Mexico): Merrill Ly de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch (Israel): Merrill Lynch (Israel): Merrill Lynch (Israel) (Israel): Merrill Lynch (Israel): Merr Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to 'Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information prepared and issued by Merrill Lynch (DIFC) is done so in accordance wi

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or



financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

This report may contain a short-term trading idea or recommendation, which highlights a specific near-term catalyst or event impacting the issuer or the market that is anticipated to have a short-term price impact on the equity securities of the issuer. Short-term trading ideas and recommendations are different from and do not affect a stock's fundamental equity rating, which reflects both a longer term total return expectation and attractiveness for investment relative to other stocks within its Coverage Cluster. Short-term trading ideas and recommendations may be more or less positive than a stock's fundamental equity rating.

BofA Securities is aware that the implementation of the ideas expressed in this report may depend upon an investor's ability to "short" securities or other financial instruments and that such action may be limited by regulations prohibiting or restricting "shortselling" in many jurisdictions. Investors are urged to seek advice regarding the applicability of such regulations prior to executing any short idea contained in this report.

Foreign currency rates of exchange may adversely affect the value, price or income of any security or financial instrument mentioned herein. Investors in such securities and instruments, including ADRs, effectively assume currency risk.

BofAS or one of its affiliates is a regular issuer of traded financial instruments linked to securities that may have been recommended in this report. BofAS or one of its affiliates may, at any time, hold a trading position (long or short) in the securities and financial instruments discussed in this report.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

BofA ESGMeter Methodology:

ESGMeter is a proprietary metric based on quantitative analysis and fundamental analyst inputs that reflects our assessment of a company's Environmental, Social and Governance-related attributes. The ESGMeter is intended to indicate a company's likelihood of experiencing stronger financial stability (higher return on equity and lower earnings and price volatility) over the next three years relative to peer group. There are three ESGMeter levels - Low, Medium, and High - which indicate whether a company has attributes most likely to translate into superior financial stability (in the case of a High level) or weaker financial stability (in the case of a Low level) over the next three years relative to its peer group. A Medium level suggests that a company exhibits ESG characteristics that are likely associated with financial stability results in line with its peer group over the next three years. Full details of our methodology, financial stability definition and disclaimers are available at BofA ESGMeter methodology. ESGMeter is not indicative of a company's future stock price performance and is not an investment recommendation or rating. ESGMeter is independent of the BofA Global Research fundamental equity analyst's investment rating, volatility risk rating, income rating or price objective for that company.

Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public inform

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Subject to the quiet period applicable under laws of the various jurisdictions in which we distribute research reports and other legal and BofA Securities policy-related restrictions on the publication of research reports, fundamental equity reports are produced on a regular basis as necessary to keep the investment recommendation current.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

